Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.OCGN · Entity 5550 | Chief Medical Officer | May 05, 2020 | May 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date May 05, 2020 · Filed May 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2030-05-05 | Direct | 109,913 |
Reported balance
After 2020-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 109,913 · Balance 109,913 F1: The options will vest annually in equal installments over three years commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest annually in equal installments over three years commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2020 Filed May 7, 2020 23:50 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOptions (Right to Buy) · Derivative | 109,913 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001192482-20-000325 · edgar.xml · derivative · entry 1 JORGENSEN DANIEL · CIK 0001529028 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,913 Underlying: Common Stock · 109,913 shares Expires 2030-05-05 F1 · derivative.exercise_date: The options will vest annually in equal installments over three years commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 01:40 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOptions (Right to Buy) · Derivative | 101,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000026 · edgar.xml · derivative · entry 1 JORGENSEN DANIEL · CIK 0001529028 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,470 Underlying: Common Stock · 101,470 shares Expires 2030-01-02 F1 · derivative.exercise_date: The options will vest annually in equal installments over three years commencing on January 2, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.